TW202334430A - 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染 - Google Patents

自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染 Download PDF

Info

Publication number
TW202334430A
TW202334430A TW111149485A TW111149485A TW202334430A TW 202334430 A TW202334430 A TW 202334430A TW 111149485 A TW111149485 A TW 111149485A TW 111149485 A TW111149485 A TW 111149485A TW 202334430 A TW202334430 A TW 202334430A
Authority
TW
Taiwan
Prior art keywords
aat
yeast
protein
recombinant
fragment
Prior art date
Application number
TW111149485A
Other languages
English (en)
Chinese (zh)
Inventor
曼弗雷德 斯坦格爾
Original Assignee
德商阿泰克醫療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商阿泰克醫療有限公司 filed Critical 德商阿泰克醫療有限公司
Publication of TW202334430A publication Critical patent/TW202334430A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/84—Pichia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
TW111149485A 2021-12-22 2022-12-22 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染 TW202334430A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21216836 2021-12-22
EP21216836.3 2021-12-22
EP22166483.2 2022-04-04
EP22166483 2022-04-04

Publications (1)

Publication Number Publication Date
TW202334430A true TW202334430A (zh) 2023-09-01

Family

ID=84980906

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111149485A TW202334430A (zh) 2021-12-22 2022-12-22 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染

Country Status (8)

Country Link
US (1) US20250057927A1 (enExample)
EP (1) EP4453233A1 (enExample)
JP (1) JP2025501746A (enExample)
AU (1) AU2022422304A1 (enExample)
CA (1) CA3241852A1 (enExample)
IL (1) IL313247A (enExample)
TW (1) TW202334430A (enExample)
WO (1) WO2023118424A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4731251A1 (en) * 2023-06-22 2026-04-29 AATEC Medical GmbH Recombinant aat from yeast to treat bacterial respiratory infections
EP4730999A1 (en) * 2023-06-22 2026-04-29 AATEC Medical GmbH Recombinant aat from yeast to treat transplants
EP4480960A1 (en) * 2023-06-22 2024-12-25 AATEC Medical GmbH A recombinant human alpha-1 antitrypsin glycoprotein
JP2026525823A (ja) * 2023-06-22 2026-08-04 エイエイテック メディカル ゲーエムベーハー 組換えヒトアルファ-1アンチトリプシン糖タンパク質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
WO2021191900A1 (en) 2020-03-26 2021-09-30 Kamada Ltd. Methods for treating infectious diseases caused by coronavirus

Also Published As

Publication number Publication date
CA3241852A1 (en) 2023-06-29
IL313247A (en) 2024-08-01
AU2022422304A1 (en) 2024-06-20
WO2023118424A1 (en) 2023-06-29
US20250057927A1 (en) 2025-02-20
JP2025501746A (ja) 2025-01-23
EP4453233A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US20250057927A1 (en) Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections
US20230414730A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
CN101333258B (zh) 一种具有抗菌及促伤口愈合功能的融合多肽
KR20160132021A (ko) 건조 분말 펩티드 약제
EP3995130A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
US9421243B2 (en) Therapy for influenza like illness
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
CN118434880A (zh) 由酵母生产的α-1抗胰蛋白酶用于治疗病毒感染的用途
EP4480960A1 (en) A recombinant human alpha-1 antitrypsin glycoprotein
KR20260030111A (ko) 재조합 인간 알파-1 항트립신 당단백질
EP4480493A1 (en) A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung
KR20080071116A (ko) 기도에 영향을 미치는 염증 질환에 있어서 활성화 단백질c의 기도 투여법
KR20220137946A (ko) 바이러스성 폐렴의 치료 방법 및 약물
WO2024261179A1 (en) Recombinant aat from yeast to treat bacterial respiratory infections
AU2022380713A1 (en) Das181 variant compositions